Yusuke Imanaka1, Maki Taniguchi1, Takehiko Doi1, Miyuki Tsumura1, Rie Nagaoka2, Maiko Shimomura1, Takaki Asano1,3, Reiko Kagawa1, Yoko Mizoguchi1, Shuhei Karakawa1, Koji Arihiro4, Kohsuke Imai5, Tomohiro Morio5, Jean-Laurent Casanova3,6,7,8, Anne Puel3,6,7, Osamu Ohara9, Katsuhiko Kamei10, Masao Kobayashi1,11, Satoshi Okada12. 1. Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Science, Hiroshima, Japan. 2. Division of Infectious Diseases Laboratory Medicine, Hiroshima University Hospital, Hiroshima, Japan. 3. St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA. 4. Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan. 5. Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. 6. Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France. 7. University of Paris, Paris, France. 8. Howard Hughes Medical Institute, New York, NY, USA. 9. Department of Applied Genomics, Kazusa DNA Research Institute, Kisarazu, Japan. 10. Department of Medical Mycology Research Center, Chiba University, Chiba, Japan. 11. Japan Red Cross, Chugoku-Shikoku Block Blood Center, Hiroshima, Japan. 12. Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Science, Hiroshima, Japan. sokada@hiroshima-u.ac.jp.
Abstract
PURPOSE: Autosomal recessive CARD9 deficiency predisposes patients to invasive fungal disease. Candida and Trichophyton species are major causes of fungal disease in these patients. Other CARD9-deficient patients display invasive diseases caused by other fungi, such as Exophiala spp. The clinical penetrance of CARD9 deficiency regarding fungal disease is surprisingly not complete until adulthood, though the age remains unclear. Moreover, the immunological features of genetically confirmed yet asymptomatic individuals with CARD9 deficiency have not been reported. METHODS: Identification of CARD9 mutations by gene panel sequencing and characterization of the cellular phenotype by quantitative PCR, immunoblot, luciferase reporter, and cytometric bead array assays were performed. RESULTS: Gene panel sequencing identified compound heterozygous CARD9 variants, c.1118G>C (p.R373P) and c.586A>G (p.K196E), in a 4-year-old patient with multiple cerebral lesions and systemic lymphadenopathy due to Exophiala dermatitidis. The p.R373P is a known disease-causing variant, whereas the p.K196E is a private variant. Although the patient's siblings, a 10-year-old brother and an 8-year-old sister, were also compound heterozygous, they have been asymptomatic to date. Normal CARD9 mRNA and protein expression were found in the patient's CD14+ monocytes. However, these cells exhibited markedly impaired pro-inflammatory cytokine production in response to fungal stimulation. Monocytes from both asymptomatic siblings displayed the same cellular phenotype. CONCLUSIONS: CARD9 deficiency should be considered in previously healthy patients with invasive Exophiala dermatitidis disease. Asymptomatic relatives of all ages should be tested for CARD9 deficiency. Detecting cellular defects in asymptomatic individuals is useful for diagnosing CARD9 deficiency.
PURPOSE: Autosomal recessive CARD9 deficiency predisposes patients to invasive fungal disease. Candida and Trichophyton species are major causes of fungal disease in these patients. Other CARD9-deficient patients display invasive diseases caused by other fungi, such as Exophiala spp. The clinical penetrance of CARD9 deficiency regarding fungal disease is surprisingly not complete until adulthood, though the age remains unclear. Moreover, the immunological features of genetically confirmed yet asymptomatic individuals with CARD9 deficiency have not been reported. METHODS: Identification of CARD9 mutations by gene panel sequencing and characterization of the cellular phenotype by quantitative PCR, immunoblot, luciferase reporter, and cytometric bead array assays were performed. RESULTS: Gene panel sequencing identified compound heterozygous CARD9 variants, c.1118G>C (p.R373P) and c.586A>G (p.K196E), in a 4-year-old patient with multiple cerebral lesions and systemic lymphadenopathy due to Exophiala dermatitidis. The p.R373P is a known disease-causing variant, whereas the p.K196E is a private variant. Although the patient's siblings, a 10-year-old brother and an 8-year-old sister, were also compound heterozygous, they have been asymptomatic to date. Normal CARD9 mRNA and protein expression were found in the patient's CD14+ monocytes. However, these cells exhibited markedly impaired pro-inflammatory cytokine production in response to fungal stimulation. Monocytes from both asymptomatic siblings displayed the same cellular phenotype. CONCLUSIONS: CARD9 deficiency should be considered in previously healthy patients with invasive Exophiala dermatitidis disease. Asymptomatic relatives of all ages should be tested for CARD9 deficiency. Detecting cellular defects in asymptomatic individuals is useful for diagnosing CARD9 deficiency.
Authors: Carlos A Arango-Franco; Marcela Moncada-Vélez; Claudia Patricia Beltrán; Indira Berrío; Cristian Mogollón; Andrea Restrepo; Mónica Trujillo; Sara Daniela Osorio; Lorena Castro; Lina Vanessa Gómez; Ana María Muñoz; Verónica Molina; Delsy Yurledy Del Río Cobaleda; Ana Cristina Ruiz; Carlos Garcés; Juan Fernando Alzate; Felipe Cabarcas; Julio Cesar Orrego; Jean-Laurent Casanova; Jacinta Bustamante; Anne Puel; Andrés Augusto Arias; José Luis Franco Journal: J Clin Immunol Date: 2018-09-28 Impact factor: 8.317
Authors: Erik-Oliver Glocker; Andre Hennigs; Mohammad Nabavi; Alejandro A Schäffer; Cristina Woellner; Ulrich Salzer; Dietmar Pfeifer; Hendrik Veelken; Klaus Warnatz; Fariba Tahami; Sarah Jamal; Annabelle Manguiat; Nima Rezaei; Ali Akbar Amirzargar; Alessandro Plebani; Nicole Hannesschläger; Olaf Gross; Jürgen Ruland; Bodo Grimbacher Journal: N Engl J Med Date: 2009-10-29 Impact factor: 91.245
Authors: Marieke De Bruyne; Levi Hoste; Delfien J Bogaert; Lien Van den Bossche; Simon J Tavernier; Eef Parthoens; Mélanie Migaud; Deborah Konopnicki; Jean Cyr Yombi; Bart N Lambrecht; Sabine van Daele; Ana Karina Alves de Medeiros; Lieve Brochez; Rudi Beyaert; Elfride De Baere; Anne Puel; Jean-Laurent Casanova; Jean-Christophe Goffard; Savvas N Savvides; Filomeen Haerynck; Jens Staal; Melissa Dullaers Journal: Front Immunol Date: 2018-10-31 Impact factor: 7.561